Anna Forrester
The Emergent BioSolutions-led Center for Innovation in Advanced Development and Manufacturing will continue the development of a therapeutic drug against Ebola under a new two-year, $19.7 million contract with the Department of Health and Human Services.
HHS said Wednesday the Emergent CIADM facility will begin advanced work to manufacture a monoclonal antibody drug as part of its public-private partnership with the Biomedical Advanced Research and Development Authority at HHS.
Emergent will apply processes and material from early-stage drug development work, provide the experimental drug for clinical studies and produce the drug at commercial volumes, the department added.
“Preventing, detecting and treating Ebola infections remains critical not only for the current epidemic in West Africa but also to minimize the impacts of future outbreaks,” said BARDA Director Robin Robinson.
“The development of this experimental drug represents significant progress in making Ebola therapeutics available.”
